Bessemer Group’s Health Catalyst HCAT Stock Holding History

Bessemer Group’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-106	Closed	-$3K	–	1932
2022 Q1	$3K	Hold	106	–	–	﹤0.01%	1679
2021 Q4	$4K	Sell	106 -151	-59%	-$6.88K	﹤0.01%	1639
2021 Q3	$13K	Buy	257 +151	+142%	+$8.23K	﹤0.01%	1313
2021 Q2	$6K	Hold	106	–	–	﹤0.01%	1408
2021 Q1	$5K	Buy	+106	New	+$5.13K	﹤0.01%	1394

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Bessemer Group's HCAT Position: Q2 2022 in Review

Bessemer Group sold out of Health Catalyst (HCAT) in Q2 2022, closing a stake of 106 shares — an estimated $3K sold.

Bessemer Group first reported a position in HCAT in Q1 2021 and held it in 5 quarters. The position peaked at $13K in Q3 2021. 179 funds tracked by Wall St. Rank hold HCAT as of Q2 2022.

Bessemer Group reported no remaining Health Catalyst position as of Q2 2022 after selling out during the quarter.
Bessemer Group sold 106 Health Catalyst shares in Q2 2022, an estimated $3K.
Bessemer Group first reported a position in Health Catalyst in Q1 2021 and held it in 5 quarters.
Bessemer Group's Health Catalyst position peaked at $13K in Q3 2021.
179 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.